Immunome (IMNM) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precigen (PGEN) has outperformed Immunome (IMNM) over the past year, gaining 144.8% versus a gain of 37.8%. Over five years, PGEN leads with a +68.0% price change compared with +9.7% for IMNM. Precigen is the larger company by market cap ($2.80 billion vs $2.31 billion), about 1.2 times the size.
Precigen converts more of its revenue into profit, with a net margin of -2588.2% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | PGEN |
|---|---|---|
| Share price | $19.55 | $7.81 |
| Market cap | $2.31B | $2.80B |
| 1-day change | +1.24% | +2.76% |
| YTD return | -10.10% | +86.84% |
| 1-year return | +37.83% | +144.83% |
| 5-year return | +9.65% | +67.96% |
| EPS (TTM) | $-2.52 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $9.68M |
| Revenue growth (YoY) | -23.23% | +146.73% |
| Net income (latest FY) | $-212.39M | $-250.64M |
| Operating margin | -3228.83% | -1141.13% |
| Net margin | -3059.99% | -2588.21% |
| 52-week high | $30.06 | $8.98 |
| 52-week low | $13.49 | $2.99 |
| Distance from 52-week high | -34.96% | -13.03% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +80.05% | +74.78% |
| Average volume | 1.20M | 5.03M |
| Shares outstanding | 118.00M | 358.04M |
| Employees | 247 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed IMNM by 107.0 percentage points over the past year.
- Precigen is more profitable, keeping -2588.2 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs -23.23%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
IMNM vs PGEN FAQ
Which is bigger, Immunome or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $2.80B compared with $2.31B for Immunome (IMNM).
Which stock has performed better over the past year, IMNM or PGEN?
PGEN returned +144.83% over the past 12 months, compared with +37.83% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.